News Quantified

EVAX – evaxion a/s - american depositary share (US:NASDAQ)

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial [Yahoo! Finance]

4/17

03:10 pm

evax

Low

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Evaxion concludes Annual General Meeting

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}